Bio-Techne Stock

Bio-Techne P/E 2024

Bio-Techne P/E

74.52

Ticker

TECH

ISIN

US09073M1045

WKN

A12ENG

As of Sep 28, 2024, Bio-Techne's P/E ratio was 74.52, a 60.71% change from the 46.37 P/E ratio recorded in the previous year.

The Bio-Techne P/E history

Bio-Techne Aktienanalyse

What does Bio-Techne do?

Bio-Techne Corp is a global company specializing in the research and development of innovative products and solutions in the field of biosciences. The company was founded in 1976 in Minneapolis and was formerly known as Techne Corporation. Since then, it has grown into an internationally renowned company through its numerous acquisitions and mergers. The company is headquartered in Minneapolis, Minnesota, USA. The business philosophy of Bio-Techne Corp is to help bioscientific researchers and clinicians around the world perform their work more effectively, efficiently, and quickly. The company works closely with its customers to provide them with suitable products and services, thereby developing innovative solutions to the challenges in bioscience. Bio-Techne Corp has various business segments, including protein platforms, diagnostics, genetic analysis, clinical controls, cell culture products, and research reagents. Each business segment offers a variety of products and services to support researchers and clinicians in their work. A key business segment of Bio-Techne Corp is the protein platform, which offers a comprehensive range of proteins, antibodies, and corresponding detection reagents. The company is known for its high-quality proteins and antibodies, which contribute to improving the research of diseases such as cancer, diabetes, and neurological and immunological disorders. Another important business segment of Bio-Techne Corp is diagnostics. Here, the company offers a wide range of clinical diagnostic products, such as tests for analyzing urea, creatinine, and bone density. The company's products help clinicians make precise diagnoses and treat patients more effectively. The genetic analysis segment offers DNA sequencing, gene expression, and genome-wide analysis products and services. These tools enable researchers to better understand the functioning of the human body by exploring the underlying genetic changes. The clinical controls segment offers product and service offerings that improve the reliability and accuracy of diagnostic systems. The company works closely with medical facilities to provide diagnostic solutions that deliver fast and accurate results. The cell culture products segment offers a complete range of solutions for cell cultivation and growth. The offering ranges from basic nutrient media and additives to culture vessels and accessories. The company's products enable researchers to culture cells in a controlled environment and under precise conditions. The last segment of Bio-Techne Corp includes research reagents. Here, the company offers a wide range of reagents used for protein, antibody, and cell function analysis and research. The products meet the needs of researchers in modern bioscience. In summary, Bio-Techne Corp is a company specialized in developing innovative solutions in bioscience, advancing science and medicine. With its products and services offered in various sectors, the company successfully helps researchers and clinicians perform their work faster, more effectively, and cost-efficiently. Bio-Techne ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Bio-Techne's P/E Ratio

The Price to Earnings (P/E) Ratio of Bio-Techne is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Bio-Techne's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Bio-Techne is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Bio-Techne’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Bio-Techne stock

What is the price-to-earnings ratio of Bio-Techne?

The price-earnings ratio of Bio-Techne is currently 74.52.

How has the price-earnings ratio of Bio-Techne changed compared to last year?

The price-to-earnings ratio of Bio-Techne has increased by 60.71% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Bio-Techne high compared to other companies?

Yes, the price-to-earnings ratio of Bio-Techne is high compared to other companies.

How does an increase in the price-earnings ratio of Bio-Techne affect the company?

An increase in the price-earnings ratio of Bio-Techne would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Bio-Techne affect the company?

A decrease in the price-earnings ratio of Bio-Techne would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Bio-Techne?

Some factors that influence the price-earnings ratio of Bio-Techne are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Bio-Techne pay?

Over the past 12 months, Bio-Techne paid a dividend of 0.24 USD . This corresponds to a dividend yield of about 0.3 %. For the coming 12 months, Bio-Techne is expected to pay a dividend of 0.24 USD.

What is the dividend yield of Bio-Techne?

The current dividend yield of Bio-Techne is 0.3 %.

When does Bio-Techne pay dividends?

Bio-Techne pays a quarterly dividend. This is distributed in the months of December, March, June, September.

How secure is the dividend of Bio-Techne?

Bio-Techne paid dividends every year for the past 21 years.

What is the dividend of Bio-Techne?

For the upcoming 12 months, dividends amounting to 0.24 USD are expected. This corresponds to a dividend yield of 0.31 %.

In which sector is Bio-Techne located?

Bio-Techne is assigned to the 'Health' sector.

Wann musste ich die Aktien von Bio-Techne kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Bio-Techne from 8/30/2024 amounting to 0.08 USD, you needed to have the stock in your portfolio before the ex-date on 8/19/2024.

When did Bio-Techne pay the last dividend?

The last dividend was paid out on 8/30/2024.

What was the dividend of Bio-Techne in the year 2023?

In the year 2023, Bio-Techne distributed 0.56 USD as dividends.

In which currency does Bio-Techne pay out the dividend?

The dividends of Bio-Techne are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Bio-Techne

Our stock analysis for Bio-Techne Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bio-Techne Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.